Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Radical Prostatectomies Clear all
Recruiting No phase listed Observational

Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities

NCT07690579
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Recurrent, Prostate Metastases
Interventions
Questionnaires, Medical Record Review
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

NCT03767244
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Androgen Deprivation Therapy (ADT), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
44
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 2 Interventional Results available

Enzalutamide in Patients With High-risk Prostate Cancer

NCT01927627
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
enzalutamide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 23, 2026, 12:40 PM EDT
Suspended Not applicable Interventional

Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy

NCT04646434
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Electroencephalography, Electromyography, Questionnaire Administration, Urodynamics (UDS)
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Completed No phase listed Observational

Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer

NCT00052481
View directory record Official record
Conditions
Prostate Cancer
Interventions
quality-of-life assessment
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 75 Years · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
13
States / cities
San Francisco, California • Washington D.C., District of Columbia • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 2 Interventional

IS-002 Phase 2 Prostate Cancer Study

NCT05946603
View directory record Official record
Conditions
Prostate Cancer
Interventions
Administration of IS-002, Firefly fluorescent imaging, robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
Drug · Device · Procedure
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 4 Interventional Results available

A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy

NCT00106392
View directory record Official record
Conditions
Erectile Dysfunction, Prostate Cancer
Interventions
Tacrolimus, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Up to 65 Years · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2010 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Not applicable Interventional Results available

Effects of Perioperative B&O Suppositories on Post-op Pain and Morphine Use After Laparoscopic Prostatectomy

NCT00863928
View directory record Official record
Conditions
Pain
Interventions
belladonna 16.2 mg and opium 60 mg suppository
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 23, 2026, 12:40 PM EDT
Not listed Not applicable Interventional

ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy

NCT02773940
View directory record Official record
Conditions
Prostate Cancer
Interventions
ClariCore System
Device
Lead sponsor
Precision Biopsy, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 23, 2026, 12:40 PM EDT
Active, not recruiting Phase 3 Interventional

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

NCT06205316
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration, Magnetic Resonance Imaging
Drug · Procedure · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • Albert Lea, Minnesota • Mankato, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 2 Interventional

Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy

NCT00090376
View directory record Official record
Conditions
Impotence, Prostate Cancer
Interventions
GPI 1485
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years to 69 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
25
States / cities
Phoenix, Arizona • La Mesa, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2008 · Synced Sep 23, 2026, 12:40 PM EDT
Terminated Phase 2 Interventional

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

NCT01340599
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
defined green tea catechin extract, placebo, immunohistochemistry staining method, immunoenzyme technique, questionnaire administration, therapeutic conventional surgery, high performance liquid chromatography, mass spectrometry
Dietary Supplement · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 23, 2026, 12:40 PM EDT
Withdrawn Phase 2 Interventional

4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy

NCT03658408
View directory record Official record
Conditions
Prostate Disease
Interventions
4-aminopyridine, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
45 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 23, 2026, 12:40 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

NCT07335796
View directory record Official record
Conditions
Prostate Cancer
Interventions
BMS-986165, Degarelix
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Not applicable Interventional

DHACM in Robotic Assisted Laparoscopic Prostatectomy (RALP)

NCT02526173
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
RALP using full nerve sparing technique, dHACM Application
Procedure · Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
40 Years to 70 Years · Male only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 1 Interventional

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

NCT05938270
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saruparib (AZD5305), Darolutamide, No Treatment
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Detroit, Michigan • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Terminated No phase listed Observational

Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer

NCT03256630
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Genomic Health®, Inc.
Industry
Eligibility
Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 23, 2026, 12:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations for Radiation Oncologists

NCT02034812
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher Questionnaire
Other
Lead sponsor
GenomeDx Biosciences Corp
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 23, 2026, 12:40 PM EDT
Recruiting Phase 3 Interventional

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

NCT06056830
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
64Cu-SAR-bisPSMA
Drug
Lead sponsor
Clarity Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Active, not recruiting Phase 2 Interventional

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

NCT04915508
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Hormone Therapy, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

NCT06085664
View directory record Official record
Conditions
Prostate Cancer, Radical Prostatectomy
Interventions
REGN5678, Piflufolastat F18
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Enrolling by invitation Not applicable Interventional

HIFEM Technology for Post-Radical Prostatectomy and Post-Holmium Laser Prostate Surgery

NCT06803602
View directory record Official record
Conditions
Holmium Laser Prostate Surgery, Radical Prostatectomy
Interventions
EMSELLA®, Sham Comparator Device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Not applicable Interventional Results available

Cold Plasma for the Reduction of Lymphoceles Following PLND

NCT02658851
View directory record Official record
Conditions
Lymphoceles Following Pelvic Lymph Node Dissection
Interventions
J-Plasma
Device
Lead sponsor
Apyx Medical
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

NCT00528866
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, docetaxel, flutamide, LHRH agonist, 3-dimensional conformal radiation therapy, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
69
States / cities
Phoenix, Arizona • Auburn, California • Cameron Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 23, 2026, 12:40 PM EDT